Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3936693 | 1.00 | HTR4 (0.51) | HTR4DRD4 | |
| SCHEMBL3540611 | 0.93 | HTR4 (0.55) | HTR4DRD4 | |
| SCHEMBL3936908 | 0.89 | USP30 (0.47) | — | |
| SCHEMBL3540628 | 0.89 | USP30 (0.47) | — | |
| SCHEMBL19175394 | 0.84 | RIPK2 (0.44) | — | |
| SCHEMBL3538922 | 0.84 | HTR4 (0.47) | HTR4DRD4 | |
| SCHEMBL3942580 | 0.84 | HTR4 (0.47) | HTR4DRD4 | |
| SCHEMBL11557104 | 0.84 | HTR4 (0.72) | HTR4DRD4 | |
| SCHEMBL3542078 | 0.82 | HTR4 (0.72) | HTR4DRD4 | |
| SCHEMBL1781337 | 0.81 | ACKR3 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| CN-101511836-A | Fused pyrimido compounds | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | CN | disclosed |
| EP-2046793-A2 | FUSED PYRIMIDO COMPOUNDS | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008040951-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008040951-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | HTR4 3043/4885DRD4 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.